Page tree

Versions Compared

Key

  • This line was added.
  • This line was removed.
  • Formatting was changed.

...

Dose formComments
Prolonged-release solution for injectionUsed for products like Buvidal, where it is the dose form (the formulation of the solution for injection) causes the prolonged release; the substance is (still) plain buprenorphine
Oral/rectal solution (and others)

Multiple intended site dose forms should be included, following the pattern that already exists for eye/ear/nose drops.  BUT not all EDQM should be added - there should be evaluation (e.g. EDQM have rejected a "Solution for injection/infusion/rectal use" concept because "it is not appropriate for safety reasons, owing to the different microbiological requirements for the routes of administration covered"

For the decision support use case, grouping concepts by their intended site is often very helpful (for example)

If there is a multiple site manufactured dose form being used by products, the appropriate administrable dose form should be created in SNOMED CT even if there are no products using this directly….since some countries/implementations will be representing the administrable concept as well as the manufactured concept.  The example for this in our list is the “Powder for intravesical solution/solution for injection” with its administrable dose form of “Intravesical solution/solution for injection”

7738943003 | Gingival (intended site) |43003 | Gingival (intended site) |8943003 | Gingival (intended site) |3738943003 | Gingival (intended site) |8943003 | Gingival (intended site) |